Close

RBC Reiterates Outperform Rating on Ariad (ARIA)

September 6, 2013 2:45 PM EDT Send to a Friend
RBC Capital today maintained an Outperform rating on Ariad Pharmaceuticals (NASDAQ: ARIA) with a price target of $28.00. Analyst Michael ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login